Since HIF-1 can act as a transcription factor for key enzymes of the glycolytic pathway and lactate transporter proteins, inhibiting the transcriptional activity of HIF-1 may be a potential measure to combat post-stroke epilepsy (Longhitano et al., 2022; Karagiota et al., 2023; Huang et al., 2022). The gene discussed is HIF1A; the disease is stroke disorder.